What does Bio -X Diagnostics do?

Bio -X Diagnostics is a wholesaler in Rochefort. Public Limited, started on 23 April 1990, 1 establishment.

What is the address of Bio -X Diagnostics?

The registered office of Bio -X Diagnostics is located at Rue de la Calestienne 38, 5580 Rochefort.

Is Bio -X Diagnostics still active?

Yes. According to the CBE (29 October 2026) Bio -X Diagnostics is active, legal situation “Normale toestand”, started on 23 April 1990.

Is Bio -X Diagnostics registered on Peppol?

Yes, Bio -X Diagnostics is registered on the Peppol network with ID 0208:0441580721.

What is the enterprise number of Bio -X Diagnostics?

The enterprise number of Bio -X Diagnostics is BE0441580721.

When was Bio -X Diagnostics founded?

Bio -X Diagnostics was founded on 23 April 1990.

Who are the directors of Bio -X Diagnostics?

According to the 2025 annual accounts, the directors of Bio -X Diagnostics are: Hendrik VAN DAM, HOLDING MAESTRO SA, FINALAB SAS.

Is Bio -X Diagnostics a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 April 1990; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did Bio -X Diagnostics make in 2025?

Bio -X Diagnostics posted a profit after taxes of € 56,097 in financial year 2025.

What is the revenue of Bio -X Diagnostics?

In its most recent annual accounts (2025), Bio -X Diagnostics reported revenue of € 6,080,783.

How much does an employee at Bio -X Diagnostics earn?

The average wage cost per full-time employee at Bio -X Diagnostics was € 67,400 in 2025: staff costs of € 1.7 million for 24.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Bio -X Diagnostics have?

According to the 2025 annual accounts, Bio -X Diagnostics has 24.6 full-time equivalents (FTE).

Bio -X Diagnostics (Public Limited) - Rochefort

Dossier Bio -X Diagnostics, printed on 29 October 2026 from databakkes.be/en/0441580721/bio-x-diagnostics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Bio -X Diagnostics from Rochefort, company number BE0441580721, closed financial year 2025 with a result of € 56,097 after tax. For that financial year Bio -X Diagnostics recorded revenue of € 6.1 million and equity of € 3.6 million. Compared with financial year 2024, the result moved from € 174,667 to € 56,097. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 30, 2026.

What it is worth Growing

€ 3.6 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 56,097

▼ 68% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 136,803

▼ 68% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.3 million.

People and assets in 2025

Full-time equivalents

24.6

▲ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 960,472 in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.7 million

▲ 17% vs 2024

€ 67,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 311,588

▲ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 205,258

▼ 46% vs 2024

€ 175,746 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 1.1 million

▲ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 93 days on average.

Taxes and wages

€ 214,863

▼ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 6,034,442 Revenue 2022: € 6,034,442 First fiscal year in the series	€ 6,040,244 Revenue 2023: € 6,040,244 Unchanged (€ 6,034,442) Favourable step	€ 5,898,700 Revenue 2024: € 5,898,700 ▼ 2% vs 2023 (€ 6,040,244) Unfavourable step	€ 6,080,783 Revenue 2025: € 6,080,783 ▲ 3% vs 2024 (€ 5,898,700) Favourable step	▲ 3%
Profit after taxes	€ 754,253 Profit after taxes 2022: € 754,253 First fiscal year in the series	€ 112,180 Profit after taxes 2023: € 112,180 ▼ 85% vs 2022 (€ 754,253) Unfavourable step	€ 174,667 Profit after taxes 2024: € 174,667 ▲ 56% vs 2023 (€ 112,180) Favourable step	€ 56,097 Profit after taxes 2025: € 56,097 ▼ 68% vs 2024 (€ 174,667) Unfavourable step	▼ 68%
Equity	€ 3,446,586 Equity 2022: € 3,446,586 First fiscal year in the series	€ 3,491,438 Equity 2023: € 3,491,438 ▲ 1% vs 2022 (€ 3,446,586) Favourable step	€ 3,626,387 Equity 2024: € 3,626,387 ▲ 4% vs 2023 (€ 3,491,438) Favourable step	€ 3,643,597 Equity 2025: € 3,643,597 Unchanged (€ 3,626,387) Favourable step
Total debts	€ 2,100,462 Total debts 2022: € 2,100,462 First fiscal year in the series	€ 1,798,709 Total debts 2023: € 1,798,709 ▼ 14% vs 2022 (€ 2,100,462) Favourable step	€ 1,708,031 Total debts 2024: € 1,708,031 ▼ 5% vs 2023 (€ 1,798,709) Favourable step	€ 1,539,275 Total debts 2025: € 1,539,275 ▼ 10% vs 2024 (€ 1,708,031) Favourable step	▼ 10%
Cash	€ 346,931 Cash 2022: € 346,931 First fiscal year in the series	€ 515,734 Cash 2023: € 515,734 ▲ 49% vs 2022 (€ 346,931) Favourable step	€ 432,349 Cash 2024: € 432,349 ▼ 16% vs 2023 (€ 515,734) Unfavourable step	€ 136,803 Cash 2025: € 136,803 ▼ 68% vs 2024 (€ 432,349) Unfavourable step	▼ 68%
Land & buildings	€ 1,312,293 Land & buildings 2022: € 1,312,293 First fiscal year in the series	€ 1,203,227 Land & buildings 2023: € 1,203,227 ▼ 8% vs 2022 (€ 1,312,293) Unchanged	€ 1,084,586 Land & buildings 2024: € 1,084,586 ▼ 10% vs 2023 (€ 1,203,227) Unchanged	€ 969,253 Land & buildings 2025: € 969,253 ▼ 11% vs 2024 (€ 1,084,586) Unchanged	▼ 11%
Retained profit	€ 971,989 Retained profit 2022: € 971,989 First fiscal year in the series	€ 1,056,077 Retained profit 2023: € 1,056,077 ▲ 9% vs 2022 (€ 971,989) Favourable step	€ 1,230,744 Retained profit 2024: € 1,230,744 ▲ 17% vs 2023 (€ 1,056,077) Favourable step	€ 1,286,840 Retained profit 2025: € 1,286,840 ▲ 5% vs 2024 (€ 1,230,744) Favourable step	▲ 5%
Dividend	€ 5,400 Dividend 2022: € 5,400 First fiscal year in the series	€ 3,000 Dividend 2023: € 3,000 ▼ 44% vs 2022 (€ 5,400) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 3,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 755,249 Bank debt 2022: € 755,249 First fiscal year in the series	€ 609,350 Bank debt 2023: € 609,350 ▼ 19% vs 2022 (€ 755,249) Favourable step	€ 378,744 Bank debt 2024: € 378,744 ▼ 38% vs 2023 (€ 609,350) Favourable step	€ 205,258 Bank debt 2025: € 205,258 ▼ 46% vs 2024 (€ 378,744) Favourable step	▼ 46%
Balance sheet total	€ 5,547,047 Balance sheet total 2022: € 5,547,047 First fiscal year in the series	€ 5,290,147 Balance sheet total 2023: € 5,290,147 ▼ 5% vs 2022 (€ 5,547,047) Unchanged	€ 5,338,858 Balance sheet total 2024: € 5,338,858 ▲ 1% vs 2023 (€ 5,290,147) Unchanged	€ 5,182,871 Balance sheet total 2025: € 5,182,871 ▼ 3% vs 2024 (€ 5,338,858) Unchanged	▼ 3%
Employees (FTE)	24.9 Employees (FTE) 2022: 24.9 First fiscal year in the series	24.5 Employees (FTE) 2023: 24.5 ▼ 0.4 vs 2022 (24.9) Unchanged	23.9 Employees (FTE) 2024: 23.9 ▼ 0.6 vs 2023 (24.5) Unchanged	24.6 Employees (FTE) 2025: 24.6 ▲ 0.7 vs 2024 (23.9) Unchanged	▲ 0.7

Key figures of Bio -X Diagnostics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 March 2027.

What happened to Bio -X Diagnostics?

What happened at Bio -X Diagnostics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Hendrik VAN DAM stepped down as director. NBB
2026 HOLDING MAESTRO SA stepped down as director. NBB
2026 FINALAB SAS stepped down as director. NBB
Mar 30, 2026 New annual accounts for financial year 2025: profit of € 56,097 (▼ 68% vs 2024). Source: NBB ↗
2024 Hendrik VAN DAM became a director. NBB
2020 HOLDING MAESTRO SA became a director. NBB
2020 FINALAB SAS became a director. NBB
Sep 10, 1990 New establishment in Rochefort. KBO

In short

From € 754,253 profit in 2022 to € 56,097 profit in 2025.

Paid € 120,554 in corporate taxes since 2022.

Best year ever: 2022, with € 754,253 profit.

Paid out € 8,400 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

HOLDING MAESTRO 51%

The stake of HOLDING MAESTRO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Bio -X Diagnostics

ADIAGENE 100%

The shares are held by HOLDING MAESTRO (51%). It owns 100% of ADIAGENE itself.

Directors

According to the 2025 annual accounts

Hendrik VAN DAM

Director

since 2024 · until 2030

HOLDING MAESTRO SA

Managing director · represented by Philippe HIVOREL

since 2020 · until 2026

FINALAB SAS

Director · represented by Julien FLORI

since 2020 · until 2026

Shareholders

HOLDING MAESTRO

51%

Participations

ADIAGENE

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de la Calestienne 38

5580 Rochefort

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0441.580.721

VAT number

BE 0441.580.721

Registered office

Rue de la Calestienne 38, 5580 Rochefort

Names & denominations

Bio -X Diagnostics

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

23 April 1990

Peppol

Active · Active since 6 Dec 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Groothandel in chemische producten voor industrieel gebruik

Groothandel in chemische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Bio -X Diagnostics

Warning lights

Financials

What happened to Bio -X Diagnostics?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions